Table 4.
Candidate Pharmacogenomic Variants Associated with DLIx Phenotype
| Variant | Gene | Chr. | Effect Allele | *β (SE) | p-value |
|---|---|---|---|---|---|
| rs8110536 | MISP | 19 | G | 0.26 (0.074) | 0.00063 |
| rs1128503 | ABCB1 | 7 | G | 0.18 (0.057) | 0.0025 |
| rs10276036 | ABCB1 | 7 | T | 0.18 (0.057) | 0.0025 |
| rs1801280 | NAT2 | 8 | C | −0.17 (0.058) | 0.0045 |
| rs2032582 | ABCB1 | 7 | A | −0.15 (0.056) | 0.0099 |
| rs1045642 | ABCB1 | 7 | G | 0.13 (0.053) | 0.015 |
| rs4148737 | ABCB1 | 7 | C | 0.14 (0.061) | 0.021 |
| rs2070744 | NOS3 | 7 | C | 0.14 (0.061) | 0.028 |
| rs738409 | PNPLA3 | 22 | G | −0.14 (0.066) | 0.035 |
| rs246221 | ABCC1 | 16 | C | 0.12 (0.057) | 0.036 |
| rs639174 | DROSHA | 5 | T | 0.14 (0.066) | 0.040 |
| rs17222723 | ABCC2 | 10 | A | 0.23 (0.12) | 0.045 |
Effect allele based on previous reports in PharmGKB (Supplemental Table 1)
*
linear additive genetic model with change in absolute lymphocyte count as the outcome with age at diagnosis, gender, and bridging therapy included in model